1519.HK
Baozun does e-commerce tools

Logistics company J&T Express Global Ltd. (1519.HK) announced on Thursday its parcel volume reached 6.6 billion in the first quarter, up 31.2% year-on-year. The company handled an average of 73.3 million parcels per day during the period, up by a similar 32.6% from a year earlier.

Southeast Asia recorded the highest growth among the company’s regions, with 1.54 billion parcels processed in the first quarter, up 50% year-on-year. Daily parcel volume in the region rose 51.6% to 17.1 million. China remained the company’s largest market, with 5 billion parcels handled in the first quarter, up 26.5% year-on-year. The average daily volume in China was 55.4 million, up 27.9%.

J&T Express had 7,100 network partners at the end of the quarter, down by 100 from the end of last year. Its number of service points increased by 100 to 19,200, while its number of sorting centers remained unchanged at 238

The company’s stock opened 4.4% higher at HK$5.19 on Thursday, closing up 3.22% at HK$5.13 by the midday break.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…